Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

Published:2019-08-02 Issue:5 Volume:36 Page:449-456
ISSN:0262-0898
Container-title:Clinical & Experimental Metastasis
language:en
Short-container-title:Clin Exp Metastasis

Author:

Carbone Federico^ORCID,Grossi Francesco,Bonaventura Aldo,Vecchié Alessandra,Minetti Silvia,Bardi Nicholas,Elia Edoardo,Ansaldo Anna Maria,Ferrara Daniele,Rijavec Erika,Dal Bello Maria Giovanna,Biello Federica,Rossi Giovanni,Tagliamento Marco,Alama Angela,Coco Simona,Spallarossa Paolo,Dallegri Franco,Genova Carlo,Montecucco Fabrizio

Funder

Ministero della Salute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10585-019-09984-z.pdf

Reference33 articles.

1. Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X (2019) Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer 19(1):558. https://doi.org/10.1186/s12885-019-5701-6

2. Raju S, Joseph R, Sehgal S (2018) Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther 7:63–75. https://doi.org/10.2147/ITT.S125070

3. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627